副甲状腺ホルモン ヒト 化学特性,用途語,生産方法
使用
Treatment of
osteoporosis, as an antiosteoporotic, in the treatment of
bone and mineral disease and disorders, bone metabolism
regulator, blood calcium regulator, and as a diagnostic aid
(pseudohypoparathyroidism; hypocalcemia).
適応症
Human rPTH (1-34) has been produced by recombinant
technologies, is now approved, and will soon be available
for the treatment of osteoporosis. It is given subcutaneously,
25 μg/day cyclically for 12 to 18 months, to increase
bone density in individuals with a history of fractures,
severe osteopenia, or osteoporosis. PTHrP (1-36)
has also been synthesized and is in early clinical trials.
brand name
Paroidin (Parke-Davis).
副甲状腺ホルモン ヒト 上流と下流の製品情報
原材料
準備製品